Welcome to our dedicated page for CURANEX PHARMACEUTICALS SEC filings (Ticker: CURX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Curanex Pharmaceuticals Inc (CURX) SEC filings page on Stock Titan provides organized access to the company’s public filings with the U.S. Securities and Exchange Commission. As a developmental-stage biotechnology company listed on the Nasdaq Capital Market, Curanex uses these documents to report on its financial condition, capital markets activities, regulatory status, and progress as it develops botanical drugs for inflammatory diseases.
Investors can review registration statements and related documents that describe Curanex’s initial public offering and the exercise of underwriters’ over-allotment options. Filings such as Form 8-K give details on unregistered sales of equity securities, related-party loans, and the repayment of promissory notes that eliminated outstanding debt and reduced future interest obligations.
Regulatory and listing matters appear in Curanex’s current reports on Form 8-K, including disclosures about a Nasdaq notice that the company’s common stock had traded below the minimum bid price required for continued listing on the Nasdaq Capital Market. These filings outline the compliance period granted to the company and potential next steps if the minimum bid price requirement is not met.
The filings page also includes documents such as Form 12b-25 (Notification of Late Filing), where Curanex explained why it could not file a Quarterly Report on Form 10-Q by the prescribed date and indicated its intention to file within the allowed extension period. Over time, investors can expect to see quarterly reports (Form 10-Q) and annual reports (Form 10-K) that provide more detailed financial statements and management discussion when available.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, explain complex sections in simpler language, and help users quickly identify information on topics such as capital structure, listing compliance, and development plans for the Phyto-N botanical drug candidate.
Curanex Pharmaceuticals Inc. (CURX)$13.24M in net proceeds, plus
The business remains pre-revenue and reported a net loss of
Curanex Pharmaceuticals (CURX) reported a Nasdaq notice that its common stock failed the $1.00 minimum bid price requirement for 30 consecutive business days. Trading on the Nasdaq Capital Market continues under “CURX”.
The company has a 180‑day compliance period until May 4, 2026 to regain compliance by having a closing bid of at least $1.00 for a minimum of ten consecutive business days (subject to Nasdaq staff discretion). If unmet, Curanex may receive an additional 180 days if it satisfies other initial listing standards and notifies Nasdaq of an intent to cure, which may include a reverse stock split. Failing that, the stock would be subject to delisting.
Curanex Pharmaceuticals Inc reported two key actions. The company issued 28,312 unregistered shares of common stock to investor Xiaohong Song under a prior subscription agreement, in exchange for $200,000 that had been subscribed contingent on its initial public offering. This share grant represents 0.1% of 28,312,500 total common shares outstanding at the time of issuance and was made under a private offering exemption.
Curanex also fully repaid two insider loans from Dian Ying Jing, the CEO’s spouse, totaling $400,000 of principal. It paid $408,537.32 in aggregate, including $8,537.32 of accrued interest at a 4.34% annual rate, and did so ahead of the 2027 maturity dates. This prepayment eliminated all of the company’s outstanding debt and removed approximately $26,182.68 of future interest charges that would have accrued through maturity.
FAQ
What is the current stock price of CURANEX PHARMACEUTICALS (CURX)?
What is the market cap of CURANEX PHARMACEUTICALS (CURX)?
